肝胆胰外科杂志2024，Vol.36Issue(8)：503-507,5.DOI:10.11952/j.issn.1007-1954.2024.08.013
肝肉瘤样癌9例临床特征及诊疗分析
Clinical features,diagnosis and treatment of hepatic sarcomatoid carcinoma in 9 cases
摘要
Abstract
Objective To summarize the clinical features,diagnosis and treatment plan and prognosis of patients with hepatic sarcomatoid carcinoma(HSC).Methods A retrospective study was conducted in 9 HSC patients,who admitted in Zhejiang Provincial People's Hospital between Jan.2012 and Mar.2024 and then were pathologically diagnosed as HSC postoperatively.Results Among the 9 HSC patients,there were 3 males and 6 females,aged from 33 to 90 years.Preoperative examination revealed elevated levels of tumor markers(AFP,CEA,CA199)in 4 cases.Preoperative imaging diagnosis of liver tumor in 8 patients and misdiagnosis of liver abscess in 1 patient.MRI examination of the tumor boundary was not clear,showing"progressive enhancement"or"peripheral enhancement".All the 9 HSC patients underwent laparoscopic liver tumor resection.The mean maximum tumor diameter was(6.24±3.98)cm.The AJCC stages were as follows:1 case of stage Ⅰ,4 cases of stage Ⅱ and 4 cases of stage Ⅳ.Three patients received postoperative chemotherapy,of which 1 patient received combined targeted therapy(Anlotinib+AG regime).The postoperative pathological manifestations were fusiform cell malignant tumor,immunohistochemical results showed CK(+)epithelioid phenotype and mesenchymal phenotype Vim(+)to varying degrees.Follow-up was conducted till to Mar.14,2024,the postoperative survival time in 9 HSC patients was 1.6-29.9 months,and the median survival time was 4.3 months.Conclusion HSC is highly malignant,and surgical resection is the preferred treatment.The strategy of HSC postoperative chemotherapy combined with target therapy and immune therapy needs to be further explored.关键词
肝肿瘤/肉瘤样癌/诊断/治疗Key words
liver tumor/sarcomatoid carcinoma/diagnosis/treatment分类
医药卫生引用本文复制引用
谢笑笑,高振宇,方正康,黄浩,张军港..肝肉瘤样癌9例临床特征及诊疗分析[J].肝胆胰外科杂志,2024,36(8):503-507,5.基金项目
浙江省公益技术应用研究项目(LGF22H160032) （LGF22H160032）
浙江省医药卫生科研项目(2022RC107,2023KY501). （2022RC107,2023KY501）
